Name (Synonyms) | Correlation | |
---|---|---|
drug391 | Cytokines dosage Wiki | 0.58 |
drug33 | ACEIs Wiki | 0.58 |
drug374 | Conventional treatment Wiki | 0.58 |
drug346 | Complement dosage Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D009102 | Multiple Organ Failure NIH | 0.33 |
D058186 | Acute Kidney Injury NIH | 0.19 |
D013577 | Syndrome NIH | 0.07 |
D055371 | Acute Lung Injury NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.07 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.06 |
There are 3 clinical trials
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Description: KDIGO AKI score
Measure: Acute Kidney Injury Time: During Intensive Care, an estimated average of 10 days.Description: Acute Respiratory Distress Syndrome yes/no
Measure: ARDS Time: During intensive care, an estimated average of 10 days.Description: Death within 30 days of ICU admission
Measure: 30 day mortality Time: 30 daysDescription: Death within 1 year of ICU admission
Measure: 1 year mortality Time: 1 yearDescription: Development of Chronic Kidney Disease
Measure: Chronic Kidney Disease Time: 60 days and 1 year after ICU admissionDescription: Sequential Organ Failure Score as a continuous variable
Measure: SOFA-score Time: During Intensive Care, an estimated average of 10 days.The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Description: KDIGO AKI score
Measure: Acute Kidney Injury Time: During Intensive Care, an estimated average of 10 days.Description: Acute Respiratory Distress Syndrome yes/no
Measure: ARDS Time: During intensive care, an estimated average of 10 days.Description: Death within 30 days of ICU admission
Measure: 30 day mortality Time: 30 daysDescription: Death within 1 year of ICU admission
Measure: 1 year mortality Time: 1 yearDescription: Development of Chronic Kidney Disease
Measure: Chronic Kidney Disease Time: 60 days and 1 year after ICU admissionDescription: Sequential Organ Failure Score as a continuous variable
Measure: SOFA-score Time: During Intensive Care, an estimated average of 10 days.In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring hospitalization in intensive care seems related to deregulation of cytokines with very high levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. In order to elucidate the mechanism of this hyper inflammatory syndrome we will measure a panel of pro and anti inflammatory cytokines, as well as known markers of macrophage activation syndrome. To determine the role of activation of the complement cascade the most important complement factors and their activation markers will be measured. The changes of those parameters will be monitored after administration of an anti-IL6R antibody therapy.
Description: Interleukine 6, soluble IL6-R, complex IL6-IL6R concentration
Measure: IL6 concentration Time: Before anti-IL6R treatment (baseline)Description: Interleukine 6 soluble IL6-R, complex IL6-IL6R variation compared to baseline value
Measure: IL6 concentration change from baseline value Time: Twice a week from day 1 to day 14 post anti-IL6R administrationDescription: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2
Measure: Complement parameters Time: Before anti-IL6R treatment (baseline)Description: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2 variation compared to baseline values
Measure: Complement parameters change from baseline values Time: Twice a week from day 1 to day 14 post anti-IL6R administrationDescription: Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18
Measure: Inflammatory cytokines baseline concentrations Time: Before anti-IL6R treatment (baseline)Description: Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18 variation compared to baseline values
Measure: Inflammatory cytokines change from baseline values Time: Twice a week from day 1 to day 14 post anti-IL6R administrationDescription: sCD25, sCD163, sCD14, glycosylated ferritin
Measure: Concentration of markers of macrophage activation Time: Before anti-IL6R treatment (baseline)Description: sCD25, sCD163, sCD14, glycosylated ferritin variation compared to baseline values
Measure: Markers of macrophage activation change from baseline values Time: Twice a week from day 1 to day 14 post anti-IL6R administration